AbbVie Inc. (NYSE:ABBV) Chairman Richard A. Gonzalez sold 193,131 shares of AbbVie stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $71.00, for a total transaction of $13,712,301.00. Following the transaction, the chairman now owns 469,623 shares in the company, valued at $33,343,233. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

AbbVie Inc. (NYSE ABBV) traded up 0.35% during midday trading on Tuesday, hitting $71.47. 4,398,003 shares of the company traded hands. AbbVie Inc. has a 12-month low of $55.06 and a 12-month high of $75.04. The firm has a market capitalization of $113.75 billion, a PE ratio of 17.58 and a beta of 1.50. The stock’s 50-day moving average is $72.12 and its 200-day moving average is $66.41. AbbVie also was the target of some unusual options trading activity on Monday. Stock traders acquired 278 put options on the company. This is an increase of approximately 121% compared to the average daily volume of 126 put options.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, July 28th. The company reported $1.42 earnings per share for the quarter, beating analysts’ consensus estimates of $1.40 by $0.02. The business had revenue of $6.94 billion during the quarter, compared to the consensus estimate of $6.93 billion. AbbVie had a net margin of 24.77% and a return on equity of 154.76%. The firm’s revenue for the quarter was up 7.6% compared to the same quarter last year. During the same quarter last year, the firm earned $1.26 earnings per share. Analysts anticipate that AbbVie Inc. will post $5.52 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, August 15th. Investors of record on Friday, July 14th will be given a $0.64 dividend. This represents a $2.56 dividend on an annualized basis and a yield of 3.58%. The ex-dividend date of this dividend is Wednesday, July 12th. AbbVie’s dividend payout ratio (DPR) is currently 62.90%.

TRADEMARK VIOLATION NOTICE: “AbbVie Inc. (NYSE:ABBV) Chairman Sells $13,712,301.00 in Stock” was posted by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/08/08/abbvie-inc-nyseabbv-chairman-sells-13712301-00-in-stock.html.

Several research firms have weighed in on ABBV. BidaskClub cut shares of AbbVie from a “buy” rating to a “hold” rating in a research report on Friday. Piper Jaffray Companies reiterated a “buy” rating and set a $85.00 price objective on shares of AbbVie in a research report on Thursday, August 3rd. Cowen and Company set a $70.00 price objective on shares of AbbVie and gave the stock a “hold” rating in a research report on Sunday, July 30th. Vetr upgraded shares of AbbVie from a “hold” rating to a “buy” rating and set a $76.28 price objective on the stock in a research report on Wednesday, July 26th. Finally, Credit Suisse Group reiterated a “neutral” rating and set a $74.00 price objective (up from $65.00) on shares of AbbVie in a research report on Thursday, July 20th. Nine analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. AbbVie currently has a consensus rating of “Buy” and a consensus target price of $75.35.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Acropolis Investment Management LLC purchased a new stake in shares of AbbVie during the second quarter worth approximately $106,000. Hudock Capital Group LLC boosted its stake in shares of AbbVie by 109.5% in the second quarter. Hudock Capital Group LLC now owns 1,542 shares of the company’s stock worth $111,000 after buying an additional 806 shares in the last quarter. First Command Financial Services Inc. boosted its stake in shares of AbbVie by 6.8% in the first quarter. First Command Financial Services Inc. now owns 1,565 shares of the company’s stock worth $102,000 after buying an additional 99 shares in the last quarter. BDO Wealth Advisors LLC purchased a new stake in shares of AbbVie during the second quarter worth approximately $115,000. Finally, Franklin Parlapiano Turner & Welch LLC purchased a new stake in shares of AbbVie during the first quarter worth approximately $108,000. 67.89% of the stock is owned by institutional investors and hedge funds.

About AbbVie

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Insider Buying and Selling by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related companies with MarketBeat.com's FREE daily email newsletter.